Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  04:00:01 2023-01-26 pm EST
577.37 USD   +0.36%
01/24ADRs End Lower; AstraZeneca, Can-Fite BioPharma Trade Actively
DJ
01/24Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
AQ
01/24Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific to Seek Acquisitions

11/16/2022 | 08:28am EST

Thermo Fisher Scientific Inc. (NYSE:TMO) will look for acquisitions. Thermo Fisher Scientific Inc. announced that on November 14, 2022, it priced an offering of $1.2 billion aggregate principal amount (the 'offering') of the following notes. $600 million aggregate principal amount of its 4.800% senior notes due 2027 (the '2027 notes'), at the issue price of 99.960% of their principal amount, and $600 million aggregate principal amount of its 4.950% senior notes due 2032 (the '2032 notes' and together with the 2027 notes, the 'notes'), at the issue price of 99.797% of their principal amount.

Thermo Fisher intends to use the net proceeds from the sale of the notes for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose.


ę S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
01/24ADRs End Lower; AstraZeneca, Can-Fite BioPharma Trade Actively
DJ
01/24Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Str..
AQ
01/24Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Ba..
CI
01/24Barclays Adjusts Thermo Fisher Scientific's Price Target to $630 From $570, Maintains O..
MT
01/23Thermo Fisher Scientific Inc. Launches CE-IVD Marked Assay to Detect Treatment-Resistan..
CI
01/19Dicot has contracted Thermo Fisher Scientific for manufacturing of LIB-01
AQ
01/13DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit
AQ
01/13Thermo Fisher Scientific Joins Momentum Labs as Founding Sponsor of New Biotech Hub in ..
AQ
01/10Transcript : Thermo Fisher Scientific Inc. Presents at 41st Annual J.P. Morga..
CI
01/06SVB Securities Adjusts Thermo Fisher Scientific's Price Target to $620 From $555, Keeps..
MT
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 889 M - -
Net income 2022 6 919 M - -
Net Debt 2022 24 790 M - -
P/E ratio 2022 32,9x
Yield 2022 0,20%
Capitalization 228 B 228 B -
EV / Sales 2022 5,75x
EV / Sales 2023 5,64x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 577,37 $
Average target price 616,75 $
Spread / Average Target 6,82%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer